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Abstract 31 
Background: Persistent transmission of severe acute respiratory syndrome 32 
coronavirus 2 (SARS-CoV-2) has given rise to a COVID-19 pandemic. Several 33 
vaccines, evoking protective spike antibody responses, conceived in 2020, are 34 
being deployed in mass public health vaccination programs. Recent data sug-35 
gests, however, that as sequence variation in the spike genome accumulates, 36 
some vaccines may lose efficacy. 37 
Methods: Using a macaque model of SARS-CoV-2 infection, we tested the effi-38 
cacy of a peptide-based vaccine targeting MHC Class I epitopes on the SARS-39 
CoV-2 nucleocapsid protein. We administered biodegradable microspheres 40 
with synthetic peptides and adjuvants to rhesus macaques. Unvaccinated con-41 
trol and vaccinated macaques were challenged with 1 x 108 TCID50 units of 42 
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SARS-CoV-2, followed by assessment of clinical symptoms, viral load, chest ra-43 
diographs, sampling of peripheral blood and bronchoalveolar lavage (BAL) 44 
fluid for downstream analysis. 45 
Results: Vaccinated animals were free of pneumonia-like infiltrates characteris-46 
tic of SARS-CoV-2 infection and presented with lower viral loads relative to con-47 
trols. Gene expression in cells collected from BAL samples of vaccinated ma-48 
caques revealed a unique signature associated with enhanced development of 49 
adaptive immune responses relative to control macaques. 50 
Conclusions: We demonstrate that a room temperature stable peptide vaccine 51 
based on known immunogenic HLA Class I bound CTL epitopes from the nu-52 
cleocapsid protein can provide protection against SARS-CoV-2 infection in non-53 
human primates. 54 
 55 
Keywords: SARS-CoV-2; animal model; macaque; vaccine; MHC Class I pep-56 










  67 
.CC-BY-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted April 26, 2021. ; https://doi.org/10.1101/2021.04.24.441228doi: bioRxiv preprint 
 3 of 43 
 
 
1. Introduction 68 
 69 
As of April 2021, over 1.6% of the world population have had confirmed COVID-19 disease and the 70 
new case rate is about one-half million per day. Less than 2 % of the world’s population are vac-71 
cinated against SARS-CoV-2[1]. Confounding efforts to reach herd immunity to COVID-19 disease 72 
include, but are not limited to the following: 1) the spread of SARS-CoV-2 mutations affecting the 73 
efficacy of current iterations of vaccines and therapeutic biologics[2], 2) the speed of SARS-CoV-2 74 
vaccine deployment, development, and manufacture, and 3) in the context of global public health, 75 
issues related to vaccine hesitancy, cold supply chain requirements, the total manufacturing cost 76 
per dose, and ease of administration. 77 
 78 
We have previously described a novel vaccine platform [3,4], which may address many of the above 79 
concerns and now report on its efficacy in a rhesus macaque model of SARS-CoV-2 infection. Ma-80 
caque models of COVID-19 disease have been previously reported and have served as critical tools 81 
for understanding disease pathology and for the development and testing of vaccines and thera-82 
peutics [5-21]. While the clinical course of SARS-CoV-2 infection in macaques is milder relative to 83 
that observed in humans [6,8,20,21], the macaque model remains the gold standard for preclinical 84 
evaluation of COVID-19 vaccines [10,19,22-27]. Our overall approach focuses on promoting protective 85 
T-cell immunity using synthetic peptides delivered in biodegradable microspheres together with 86 
Toll-like receptor (TLR) 4 and 9 adjuvants and differs from current COVID-19 vaccines against spike 87 
proteins. The synthetic peptide sequences applied are based on known immunogenic HLA Class I 88 
bound epitopes that have previously been characterized in either SARS-CoV-1 [28] or SARS-CoV-2 89 
[29-31] infections. We provide evidence that application of this vaccine platform in SARS-CoV-2 chal-90 
lenged macaques provides protection from pneumonia-like pathology observed in virally chal-91 
lenged but unvaccinated control non-human primate (NHP) subjects, reduces viral loads as com-92 
pared to unvaccinated controls, and induces changes in the gene expression patterns in recovered 93 
BAL cells consistent with enhanced antigen presentation capacity and markers of T-cells. 94 
 95 
2. Materials and Methods 96 
 97 
A. Macaque MHC Class I Typing  98 
 99 
The MHC Class I genes of a cohort of 15 rhesus macaques (Envigo, Alice, TX, USA) were molecu-100 
larly-typed by the University of Wisconsin-Madison National Primate Research Center. Mamu 101 
(Macaca mulatta) MHC class I alleles were typed amplifying the genomic DNA of each subject using 102 
a panel of specific primers for exon 2 of all known MHC-A and MHC-B alleles encoded by each 103 
subject’s target DNA. Resulting amplicons were sequenced by the Illumina MiSeq method [32]. The 104 
primer panel contained specific primer pairs able to amplify all possible MHC-A and MHC-B alleles 105 
encoded by each macaque. Sequencing data analysis provided a high-resolution haplotype for the 106 
MHC-A and MHC-B alleles carried by each subject. Following analysis, we selected four of the 15 107 
macaques for vaccination based on peptide MHC binding predictions as described below. 108 
 109 
B. Vaccine Design/Peptide Selection and Manufacture 110 
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In silico design and selection of SARS-CoV-2 CTL epitopes. 112 
The overall strategy and rationale used in the selection of synthetic peptides used to stimulate po-113 
tential CTL immune responses in SARS-CoV-2 infected humans has been previously described [3,4]. 114 
We selected SARS-CoV-2 nucleoprotein as the target of CTL attack based on the following rationale: 115 
1) survivors of SARS-CoV-1 have shown a memory T-cell response to nucleoprotein at least 2 years 116 
after infection [28], 2) there is >90% amino acid sequence homology between SARS-CoV-1 and SARS-117 
CoV-2 nucleoprotein (the homology for the selected CTL epitopes used in this report is 100%) [33], 118 
and 3) in general, there is a lower frequency of mutations resulting in amino acid substitutions (rel-119 
ative to Spike protein) that might affect the immunogenicity of the selected CTL epitopes repre-120 
sented by synthetic peptides within the vaccine formulation [34]. The lower mutation frequency may 121 
reflect the hypothesis that amino acid substitutions in nucleoprotein may impact viral fitness [35]. 122 
We reviewed previous literature and MHC peptide-binding databases [36] and selected five amino 123 
sequences representing SARS-CoV-2 nucleoprotein with predicted strong in vitro affinity for HLA 124 
Class I molecules[37], and/or documented or predicted immunogenic potential[4,28-31,33,38,39]. To-125 
gether this set of peptides yielded potential broad coverage of HLA haplotypes (>90% worldwide) 126 
(Supplemental data, Table S1A). The predicted binding of this set of peptides was examined within 127 
the MHC genotypes of the cohort of 15 rhesus macaques [40] available to us and the best correspond-128 
ence between selected peptides and rhesus MHC Class I genotype was selected (Supplemental 129 
data, Table S1B). Because the predicted peptide macaque MHC binding coverage for the peptide 130 
LLLDRLNQL was incomplete in the available genotypes, we added an additional peptide (AS-131 
AFFGMSR) with predicted strong Mamu MHC Class I binding to the formulation for a total of six 132 
peptides. 133 
 134 
Microsphere preparation and adjuvant formulation 135 
The peptide epitopes used in this study were delivered in vivo by intratracheal instillation of a 136 
formulation of Poly-L-lactide-co-glycolide (PLGA) microspheres containing the corresponding syn-137 
thetic nine-mer peptides and TLR-9 agonist CpG oligonucleotide adjuvant in a vehicle containing 138 
TLR-4 agonist monophosphoryl lipid A (MPLA). The rationale for the choice of the delivery plat-139 
form and the basic manufacturing scheme used in production has been previously reported [3,4,41]. 140 
Briefly, room temperature solutions of a synthetic peptide, CpG oligonucleotide, and mannose were 141 
mixed with a solution of PLGA in acetone/water followed by sonication. The formulation was then 142 
processed through a precision spray-drying device (Buchi Corporation, New Castle, DE, USA) and 143 
passed through a drying chamber (air at room temperature) to allow evaporation of the acetone. 144 
The dry microsphere stream was analyzed in real-time through a laser particle size analyzer (Spray-145 
Tech, Malvern Instruments, Malvern, PA) before collection (Buchi cyclone drier) as a dry powder 146 
for reconstitution at the time of delivery using a 2% DMSO aqueous solution containing MPLA (20 147 
g/ml). Each microsphere contained peptide loaded at approximately 0.1% by weight and CpG 148 
0.01% by weight. Monitoring of the microsphere diameters allowed the production of microspheres 149 
with a mean diameter of 10 ± 2 microns. This diameter was selected for formulation to ensure de-150 
livery via phagocytosis of no more than 1-4 microspheres per antigen-presenting cell (APC) which 151 
have an average diameter of 13 microns [3]. cGMP manufacturing protocols were employed using 152 
GMP grade synthetic peptides (Peptides International, Louisville, KY, USA), CpG oligonucleotides 153 
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(Trilink Biosciences, San Diego, CA, USA), and MPLA (Avanti Polar Lipids, Alabaster, AL, USA). 154 
The CpG oligonucleotide and MPLA used in this study were manufactured using the same chemical 155 
compositions as equivalent materials used in FDA-approved vaccines. Assessment of thermal sta-156 
bility of the synthetic peptides within the microspheres has been previously reported [3]. Peptide 157 
content and structure in microspheres were determined by HPLC after two months of room tem-158 
perature storage. We found that over 99% of the peptide was maintained structurally intact (data 159 
not shown).  160 
 161 
C. Animal Studies 162 
 163 
Ethics statement 164 
The animal research protocols used in this study were performed in strict accordance with the rec-165 
ommendations in the Guide for Care and Use of Laboratory Animals, Eighth Edition (National 166 
Academy Press, Washington, D.C., 2011). The University of Texas Medical Branch (UTMB) facility 167 
where these studies were conducted is accredited by the Association for Assessment and Accredi-168 
tation of Laboratory Animal Care. The protocols were approved by the UTMB Institutional Animal 169 
Care and Use Committee (Protocol Numbers 2004051 [natural history/control study] and 2003033 170 
[vaccination study]) and complied with the Animal Welfare Act, the U.S. Public Health Service Pol-171 
icy, and other Federal statutes and regulations related to animals and experiments involving ani-172 
mals. All hands-on manipulations, including immunizations and biosampling, were performed 173 
while animals were sedated via ketamine (5 mg/kg)/dexmedetomidine (0.025 mg/kg) intramuscular 174 
injection. All efforts were made to minimize suffering. 175 
 176 
Macaques 177 
Adult Indian origin rhesus macaques (Macaca mulatta, n = 7 [5 male, 2 female], 46-48 months old) or 178 
Vietnamese origin cynomolgus macaques (Macaca fascicularis, n = 1 female, 84 months old), individ-179 
ually identified via unique tattoo, were obtained from Envigo/Covance (Alice, Texas, USA). All an-180 
imals were considered healthy by a veterinarian before being placed on study.  Macaques were 181 
individually housed in stainless steel nonhuman primate caging equipped with squeeze backs for 182 
the duration of the studies. For continuous core body temperature measurements, a DST micro-T 183 
implantable temperature logger (Star–Oddi, Gardabaer, Iceland) was surgically implanted into the 184 
peritoneal cavity of each animal prior to study initiation; data recording was set to 10- or 15-min 185 
intervals for control and vaccinated macaques, respectively. Certified primate Diet 5048 was pro-186 
vided to the macaques daily. Drinking water (RO) was provided ad libitum through an automatic 187 
watering system. To promote and enhance the psychological well-being of the animals, food enrich-188 
ment consisting of fresh fruits and vegetables was provided daily. Environmental enrichment in-189 
cluding various manipulatives (Kong toys, mirrors, and puzzles) was also provided. 190 
 191 
D. Immunization, Virus Challenge, Post-Challenge Monitoring and Biosampling 192 
 193 
Immunization and ELISPOT analysis 194 
Immunizations were performed on the selected MHC-typed rhesus macaques (n = 4) via ultra-195 
sound-guided inguinal lymph node injection (LN) and/or intratracheal instillation (IT). Twenty mg 196 
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of vaccine microsphere preparation in 1ml was used for each LN injection (two injections / dose / 197 
animal) and 100mg of vaccine microspheres in a 5 ml volume was used for each IT administration. 198 
Specifically, on Day -51 (51 days prior to virus challenge), two of the macaques (Figure 1) were 199 
administered 2 mL of vaccine via LN injection (1 mL per node). Subsequent administration of the 200 
vaccine occurred via the IT route (5 mL) only as described previously[42].  Remaining vaccine 201 
doses, administered on Days -28 and -14, were delivered via IT only (5 mL per dose) to the rhesus 202 
vaccination group.  On Days -44, -21, and -7 (7 days post-vaccination), femoral vein peripheral 203 
blood (8 mL) was collected from each animal into a BD Vacutainer® CPTTM Cell Preparation Tube 204 
with Sodium Heparin (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and processed 205 
to peripheral blood mononuclear cells (PBMCs) per manufacturer instructions. Collected PBMCs 206 
were assessed for immunoreactivity via ELISPOT. In brief, ELISPOT assay plates (MabTech Inc., 207 
Cincinnati, OH, USA) specific for the detection of primate IFN were used according to manufac-208 
turer instructions. BAL cell concentrations were adjusted to 1 x 105 cells per mL in a complete growth 209 
medium. Diluted BAL cells were dispensed (100µL/well) into a 96-well plate after which 100µL of 210 
complete growth medium (CGM, negative control), Concanavalin A in CGM at 10 µg per well (pos-211 
itive control), and various concentrations of specific (i.e., immunizing) and non-specific peptides 212 
(Supplemental data, Table S1B) were added. Peptides used for immunization were added to wells 213 
at a concentration of 50 µM. All samples were assayed in duplicate. Plates were incubated at 214 
37°C/5% CO2 for 20-22 hours after which plates were thoroughly washed. Conjugated detection 215 
antibody was then added and incubated followed by additional washing. Wells were developed  216 
 217 




Figure 1 Legend. Schematic of the experimental protocol. Unvaccinated (control) macaques are 222 
represented by blue coloring. Vaccinated macaques are represented by red coloring. Overlapping 223 
tasks are represented by purple coloring. Graphic created with BioRender.com. 224 
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using TMB as a substrate. Counts were performed at Cellular Technology Corporation (Shaker 225 
Heights, OH, USA) using an Immunospot Analyzer and all well images were quality-controlled on 226 
site. All spot-forming cell counts reported are the result of averaging counts from the duplicate 227 
50µM immunization-specific peptide wells.  228 
 229 
Virus challenge 230 
On Day 0, macaques were administered 1-5 ×108 TCID50 SARS-CoV-2 (USA_WA1/2020) via com-231 
bined mucosal atomization (1 mL as delivered using a MAD NasalTM Intranasal Mucosal Atomiza-232 
tion Device per manufacturer instructions) and intratracheal instillation (4 mL). Intratracheal instil-233 
lations were performed as described above for delivery of the vaccine. The virus suspension was 234 
prepared on the day of challenge from frozen seed stock (kindly provided by Dr. Chien-Te [Kent] 235 
Tseng at UTMB) initially generated (one passage) in Vero C1008 (E6) cells (BEI Resources, NR-596, 236 
Lot 3956593) from original material provided by the Centers for Disease Control and Prevention in 237 
January 2020. Next-generation sequencing confirmed a 100% consensus sequence-level match to the 238 
original patient specimen (GenBank accession MN985325.1).   239 
 240 
Post-challenge monitoring and chest radiography 241 
Animals were monitored and scored twice daily for clinical signs of disease including alterations in 242 
activity/appearance (i.e., hunched posture), food consumption/waste output, and were scored 243 
based on general appearance, activity, food consumption, and outward changes in breathing pat-244 
terns. Prospectively defined criteria that required immediate euthanasia included severe dyspnea 245 
and/or agonal breathing and prostate posture/reluctance to move when stimulated. No animals met 246 
endpoint criteria during the study. Ventrolateral chest radiography was performed on the days in-247 
dicated (Figure 1) using a portable GE AMX-4+ computed radiography system per manufacturer 248 
instruction. DICOM data files were independently evaluated by two independent investigators 249 
blinded to group assignment with large animal imaging experience via a four-pattern approach 250 
(analyses of consolidation, interstitial areas, nodules or masses, and atelectasis). 251 
 252 
Biosampling 253 
Blood, nasal cavity samples, and BAL fluid were collected at the indicated times (Figure 1). Femoral 254 
vein peripheral blood was collected via Vacutainer® into standard collection tubes containing eth-255 
ylenediaminetetraacetic acid (EDTA). Hematology was performed on EDTA blood using the Abaxis 256 
VETSCAN® HM5 Hematology Analyzer (Abaxis, Inc., Union City, CA, USA). Nasal cavity samples, 257 
collected using sterile cotton-tipped medical swabs, were placed into 0.5 mL sterile phosphate-buff-258 
ered saline (PBS) for viral load analysis. For BAL fluid collection, animals were sedated as previ-259 
ously described and placed in ventral recumbency. The trachea was visualized and cannulated by 260 
an appropriately sized rubber feeding tube. Following the placement of the feeding tube, 20mL of 261 
sterile PBS was introduced into the lung and recovered manually through the feeding tube via sy-262 
ringe. This was repeated for a total of 40mL per animal. The total collected volume from each animal 263 
(10-30mL) was pooled and centrifuged under ambient conditions (10 min at 500 x g) after which the 264 
supernatant was removed. The resulting cell pellet was resuspended in 2 mL of sterile PBS. From 265 
this, 1 mL was used for ELISPOT analysis as described for PBMCs. The remaining volume was used 266 
for viral load analysis and gene expression profiling. 267 
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E. Viral Load Analysis 268 
 269 
Infectious viral load (TCID50) 270 
Nasal swab and BAL cells suspension samples were serially diluted and incubated with 2×104 Vero 271 
C1008 (E6) cells (BEI Resources, NR-596, Lot 3956593) in 100 l of culture medium (MEM/2% FBS) 272 
in 96-well flat-bottom plates (n = 5 replicate wells per dilution). Each plate contained negative and 273 
positive control wells inoculated with culture medium and diluted virus stock, respectively. Cul-274 
tures were incubated at 37°C/5% CO2 for 96h after which cytopathic effect was measured via mi-275 
croscopic observation. The TCID50/mL value for each sample was calculated as previously de-276 
scribed[43]. Macaque C75243 (cynomolgus) was not included in this study.  277 
 278 
qRT-PCR 279 
Nasal swab and BAL cell suspension samples (50L) were added to TRIzol® LS Reagent (250L) 280 
and allowed to incubate under ambient conditions for 10 min. Samples were processed to RNA 281 
using Zymo Direct-zolTM RNA Mini Prep kits per manufacturer instructions. RNA samples were 282 
analyzed via qRT-PCR targeting the SARS-CoV-2 E gene. Probe (Integrated DNA Technologies, 283 
Coralville, IA, USA) was labeled at the 5’-end with fluorophore 9-carboxyfluoroescein (6-FAM) and 284 
included an internal quencher (ZEN) and a 3’-end quencher (IowaBlackFQ, IABkFQ). Master Mix 285 
was prepared by combining forward primer (250 nM, 5’-ACAGGTACGTTAATAGTTAATAGCGT-286 
3’), reverse primer (250 nM, 5’-ATATTGCAGCAGTACGCACACA-3’), and probe (375 nM, 5’-287 
6FAM-ACACTAGCC/ZEN/ATCCTTACTGCGCTTCG-IABkFQ-3’) with 12.5L of 2X QuantiFast 288 
Probe Mix (QIAGEN), 0.25L of 2X QuantiFast RT Mix (QIAGEN), and PCR-grade water (fill to 20 289 
L). To the Master Mix, a test sample (5L) was added resulting in a final volume of 25L per reac-290 
tion. Real-time analysis was performed using the Bio-Rad CFX96TM Real-Time PCR Detection Sys-291 
tem. Thermocycling conditions were as follows:  Step 1, 1 cycle, 50°C for 10 minutes; Step 2, 1 cycle, 292 
95°C for 10 minutes; Steps 3-5, 45 cycles, 95°C for 10 seconds, 60°C for 30 seconds, single read. Neg-293 
ative controls included reaction mixtures without RNA. For quantification purposes, viral RNA ex-294 
tracted from the virus seed stock with a known TCID50/mL titer was used. All qRT-PCR results are 295 
expressed as TCID50/mL equivalents. Macaque C75243 (cynomolgus) was not included in this study. 296 
 297 
F. Gene Expression Profiling 298 
 299 
BAL samples were processed to RNA as described above for qRT-PCR analysis. RNA quantity and 300 
quality were assessed using a NanoDropTM Lite Spectrophotometer (ThermoFisher Scientific, Wal-301 
tham, MA, USA). Samples, normalized to 20ng/L, were analyzed by NanoString Technologies (Se-302 
attle, WA, USA) using the nCounter® SPRINT™ Profiler gene expression profiling using the Non-303 
Human Primate Immunology V2 Panel containing 754 genes that encompass 17 immune-related 304 
signaling pathways with isoform coverage for both Macaca mulatta and Macaca fascicularis. Probe 305 
sets that did not cover both Macaca species were eliminated resulting in a probe set of 730 genes. 306 
Raw gene expression data sets received from NanoString Technologies were processed to remove 307 
background signals and normalized using the nSolverTM V.3.0 digital analyzer software. Back-308 
ground signal correction was accomplished by subtracting the NanoString negative control genes. 309 
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Gene expression normalization was performed using the 16 internal reference genes included in the 310 
panel. 311 
 312 
G. Study Termination 313 
 314 
At scheduled study termination time points (14 and 21 days post-challenge for vaccinated and con-315 
trol macaques, respectively), animals were humanely euthanized via intravenous administration of 316 
a pentobarbital-based euthanasia solution under deep anesthesia followed by bilateral thoracotomy. 317 
 318 
H. Statistical Analysis 319 
 320 
Descriptive statistics were performed using Microsoft Excel. Hypothesis testing was performed by 321 
considering the null hypothesis of the absence of an association between the compared variables. 322 
The statistical strength of associations of continuous data was tested using Students t-testing. Qlu-323 
core Omics Explorer 3.5 (Qlucore), Metascape (Metascape.org) was used to identify the discriminat-324 
ing variables within the NanoString gene expression data sets from BAL sample analysis that were 325 
most significantly different between vaccinated and control subjects. The identification of signifi-326 
cantly differential variables between the two groups was performed by fitting a linear model for 327 
each variable. The set of genes (87 variable genes out of a total of 730 genes) was identified using a 328 
p-value of 0.05, at least a three-fold change, and a q-value cutoff of 0.1. P-values were adjusted for 329 
multiple testing using the Benjamini-Hochberg method [44]. Gene expression data were scaled to a 330 
mean = 0 and a variance = 1 before clustering. Hierarchical clustering of gene expression in BAL was 331 
performed using a supervised weighted average linkage two comparisons approach. The metric 332 
used in scaling dendrogram arms was Pearson's correlation coefficient. 333 
 334 
3. Results 335 
 336 
A. Primary Clinical Outcomes 337 
 338 
Clinical signs, body temperature alterations and hematology. 339 
Following SARS-CoV-2 challenge, outward clinical signs measured in control macaques included 340 
acute mild lethargy and respiratory distress. All vaccinated animals were normal throughout the 341 
post-challenge study period. Core body temperatures, as measured via implanted Star-Oddi DST 342 
temperature loggers, demonstrated a disruption in the diurnal cycle and mild fever lasting 2-5 days 343 
post-challenge in all four-control animals (Figure 2, top panels). Conversely, only two of the four 344 
vaccinated macaques (RA1693 and RA3797) presented with similar findings, although diurnal cycle 345 
disruption was of shorter duration (1-2 days) and the febrile response was milder (Figure 2, bottom 346 
panels). No alterations were measured in the remaining two vaccinated animals. Prior to virus chal-347 
lenge, vaccinated macaques presented with occasional disruptions in the diurnal temperature asso-348 
ciated with the vaccination procedure (Supplemental Data, Figure S1).  349 
 350 
Automated hematology analyses were performed on peripheral blood samples (Supplemental 351 
Data, Figure S2). Overall, the number of white blood cells was significantly increased in control 352 
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Figure 2 Legend. Core body temperature alterations in control and vaccinated macaques follow-357 
ing SARS-CoV-2 challenge. For each animal, seven days of pre-challenge baseline temperature 358 
measurements are shown. Each tick on the x-axis represents 6 hours or 36 individual logger meas-359 
urements.  360 
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subjects on post-challenge days 3 and 5. We observed general lymphopenia in all macaques on day 361 
1 post-challenge. By day 3 post-challenge, lymphocyte counts significantly increased in vaccinated 362 
subjects relative to unvaccinated control subjects. Peripheral blood monocyte counts generally 363 
peaked on days 1 through 5 in all animals but remained significantly elevated in vaccinated ma-364 
caques at the end of the study. Neutrophil counts generally rose by day 1 post-challenge in all sub-365 
jects. There was a transient significant elevation in neutrophils on day 7 post-challenge in vaccinated 366 
animals. 367 
 368 
Viral load 369 
Following SARS-CoV-2 challenge, nasal swab and BAL fluid samples were collected throughout the 370 
post-challenge period for analysis of infectious viral load and viral RNA via TCID50 and qRT-PCR 371 
assays, respectively. Infectious virus was measured from nasal swabs of control and vaccinated ma-372 
caques beginning one-day post-challenge (Figure 3 [top panel]). By Day 7, 3 of the 4 unvaccinated 373 
animals continued to demonstrate infectious viral shedding, albeit at low levels. In contrast, infec-374 
tious virus could be measured in only one of the vaccinated macaques at the same time point. By 10 375 
days post-challenge, infectious viral loads were undetectable in nasal swab samples from all ani-376 
mals. Viral RNA in nasal swabs generally reflected infectious viral loads. By Day 7, three of the four 377 
vaccinated animals demonstrated a 100-fold decrease in nasal swab viral RNA relative to the un-378 
vaccinated controls (Figure 3 [bottom panel]). By 14 days post-challenge, SARS-CoV-2 RNA levels 379 
were undetectable in nasal swab samples from all subjects. Infectious viral load data were used to 380 
calculate an average viral clearance rate post-challenge for each rhesus macaque. The average viral 381 
clearance rate from Days 2 through 10 was 4-5 fold higher in two of the four vaccinated macaques 382 
(RA1693 and RA3797) relative to the unvaccinated controls (Supplemental data, Figure S3).  383 
 384 
Macaque chest radiography 385 
SARS-CoV-2 challenge in unvaccinated controls resulted in mild-to-moderate lung abnormalities, 386 
similar to those previously reported for macaques [6,15,16,20,45-48]. These were predominantly lim-387 
ited to the caudal lung relative to baseline images, peaked 3-5 days post-challenge, and were quali-388 
tatively characteristic of subclinical or mild-to-moderate human COVID-19 (e.g., ground-glass opac-389 
ities with or without reticulation, paving, silhouetting, and/or linear opacities). The mild to moder-390 
ate interstitial pneumonitis seen on the ventrolateral chest radiographs of unvaccinated subjects are 391 
consistent with focal infiltrates representing a complex of interstitial macrophages, neutrophils, and 392 
plasmacytoid dendritic cells [49]. Abnormalities in control animals resolved by Days 10-21. In con-393 
trast, vaccinated macaques lacked the appearance of ground-glass opacities in all regions of the lung 394 
throughout the study period (Figure 4 and Supplemental data, Figures S4-S9). We did observe, 395 
however, modest bilateral increases in reticulation in vaccinated macaques on Days 3-5, but these 396 
abnormalities also resolved by Day 10-21. Bronchoalveolar lavage has been reported to affect com-397 
puterized tomography X-ray results in healthy rhesus macaques [50]. In our study, however, the 398 
pattern of reported changes in vaccinated (i.e., healthy) animals on which BAL was performed was 399 
more similar to increases in reticulation versus the patchy consolidations observed in the unvac-400 
cinated controls.  401 
  402 
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Figure 3 legend. Viral load in nasal swab samples as measured via TCID50 assay (top) and qRT-407 
PCR (bottom). The LLOD of the plaque assay was 150 units. Red symbols are vaccinated rhesus 408 
macaques, control unvaccinated rhesus subjects are shown in green symbols.  409 
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Figure 4 Legend. Representative chest radiographs of control and vaccinated macaques follow-414 
ing SARS-CoV-2 challenge. As shown, control macaques (left columns A and B) demonstrated a 415 
progression of pulmonary infiltrates during the acute period (Days 2-5) of disease post-challenge. 416 
In contrast, vaccinated macaques (right columns C and D) lacked similar abnormalities. White ar-417 
rows indicate areas of mild to moderate pulmonary infiltrates seen as ground glass consolidations. 418 
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B. Secondary Outcomes 419 
 420 
Analysis of gene expression patterns in BAL cells 421 
We identified a set of 87 genes in BAL samples collected 5-7 days post-challenge from control ani-422 
mals with statistically significant differential expression (as measured from changes in accumula-423 
tion of their specific transcripts) versus BAL samples collected from vaccinated animals during the 424 
same time points (Figures 5 and 6). We selected to focus on the Day 5 and Day 7 samples to capture 425 
a possible peak of adaptive immune responses to SARS-CoV-2 challenge as suggested by previous 426 
reports [51,52]. Several of the identified differentially regulated genes were of particular interest in 427 
the context of adaptive viral T cell immunity (Tables 1 and 2). Several differentially regulated im-428 
mune response genes laying outside the main window of interest (i.e., Day 5 alone, Day 7 alone, or 429 
Day 10 alone) were also identified (Tables 1 and 2 and Supplemental data, Figure S10). For exam-430 
ple, on Day 5 in unvaccinated macaques, we found up-regulation of IFIT3 and IL-1RAP. The ex-431 
pression levels of these transcripts have been previously reported to correlate with viral loads in a 432 
SARS-CoV-2 rhesus macaque model of COVID-19 disease [5]. 433 
 434 
In BAL samples collected on Days 5 and 7, we observed statistically significant up-regulation of 435 
MHC Class I genes, MHC Class II and associated accessory genes (CD74 invariant chain, HLA-DM), 436 
and T cell markers (CD8 and IL2) in the vaccinated group relative to the unvaccinated control ma-437 
caques. We also observed statistically significant down-regulation of Interferon alpha 2 (IFNA2), 438 
the negative regulator of T cell expansion, PD-L1, the decoy receptor for IL1α and IL1β inhibiting 439 
signaling, and FoxJ1, a regulator of Th1 cell activation [53] in the vaccinated group relative to the 440 
unvaccinated control macaques.. This pattern suggests enhanced antigen presentation and CD 4/8+ 441 
T cell response capacity in BAL cells from vaccinated macaques relative to the controls. In control 442 
animals, we observed up-regulation of several genes (CCR1, CSF3R, IFNA2, IL-1RN, IL-1RAP, IL-443 
1R2, and SOXS3) previously reported to be activated during SARS-CoV-2 infection in rhesus ma-444 
caques [5]. These genes appeared to be down-regulated, relative to controls, in vaccinated macaques. 445 
 446 
The vaccine formulation containing synthetic peptide cytotoxic T cell epitopes, CpG, and MPLA 447 
adjuvants was delivered primarily via intratracheal instillation. While we did not observe any ad-448 
verse clinical signs of respiratory distress in vaccinated subjects, we examined BAL cell gene ex-449 
pression for lymphokines and cytokines associated with the observed mixed Th1/Th2 patterns ob-450 
served in asthma [54] (Supplemental data, Figures S11 and S12). In BAL samples collected on Days 451 
5 and 7, we did not observe significant differences in expression of IL4, IL5, IL6, IL9, IL10. IL13, 452 
CXCL10, CCL5, CCL7, CCL22, CX3CL1, or CXCL1. We did observe a general trend of higher ex-453 
pression for many of the cytokines in BAL cell samples collected from vaccinated macaques pre-454 
challenge compared to unvaccinated pre-challenge controls. This effect was generally transient, di-455 
minishing by Day 5 post-challenge. This pattern of cytokine and lymphokine expression did not 456 
suggest that BAL cells assumed a phenotype associated with a Th2 response. 457 
  458 
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Figure 5 legend. Hierarchical clustering of 484 
gene expression in BAL samples collected 485 
from control and vaccinated macaques 5- 486 
and 7- days post SARS-CoV-2 challenge. 487 
Heatmap shows significantly (p<0.05) up-488 
regulated (red) genes (63 genes > 3-fold) 489 
and down-regulated (green) genes (24 490 
genes < 1/3 fold) from a total of 730 genes 491 
analyzed using the NanoString Non-Hu-492 
man Primate Immunology V2 Panel and 493 
identifies a set of genes possibly associated 494 
with protection from SARS CoV-2 chal-495 
lenge.  496 
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Figure 6 Legend. Comparison of selected transcripts up- or down-regulated in collected BAL 501 
samples 5-7 days post-challenge. Y-axis values represent fold differences in average scaled 502 
counts. Green bars and red bars represent control and vaccinated macaques, respectively. P-values 503 
below 0.05 were considered significant.  504 
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Table 1 - Differentially regulated genes in BAL cells obtained from SARS-CoV-2 challenged vac-505 
cinated versus control macaques 506 
 507 
Up-regulated Transcripts on Days 5 and 7 Post-Challenge1 
Gene ID Function Distribution Gene ID Function Distribution 
Mamu MHC1 A 
Antigen presentation to CD8+  
T cells1 
Low cell type 
specificity1 CD8 
Co-receptor for TCR binding 
to MHC C1 T cells 
Mamu MHC1 B 
Antigen presentation to CD8+  
T cells 
Low cell type 
specificity 
IL2 
Differentiation/maturation of  
T-cells  
CD4+ and 
CD8+ T cells 
TAPBP MHC Class I Antigen presen-
tation 
Low cell type 
specificity 
CD81 Costimulatory signal with 
CD3 
Low cell type 
specificity 




CD9 Cell adhesion, recognized by 
CD81 
Low cell type 
specificity 
HLA-DQA12 




Inhibitor of the complement 
membrane attack complex 
Low cell type 
specificity 
HLA-DQB12 
Antigen presentation to CD4+  
T cells 
Professional 
APC CD24 Cell adhesion molecule 
Eosinophils 
and B cells 
CD74 




High affinity receptor for 
thrombospondin-1 
Low cell type 
specificity 
HLA-DMA 





Ligand of the T-lymphocyte 
CD2 glycoprotein 
Low cell type 
specificity 




CD164 Facilitates adhesion of CD34+ 
cells 
Low cell type 
specificity 
Up-regulated Transcripts on Day 5 or 7 Post-Challenge Up-regulated Transcripts on Day 10 Post-Challenge 
IL17 B Proinflamatory cytokine 
Low cell type 
specificity IL6R 
Low affinity receptor for Inter-
leukin 6. Neutrophil 
CX3CL1 
Chemotactic for T cells and 
monocytes 
Low cell type 
specificity 
ABL1 
Tyrosine-protein kinase, role 
cell growth and survival 
Low cell type 
specificity 
CD99 Facilitates T cell adhesion 
Low cell type 
specificity TYK2 
Tyrosine-protein kinase Initia-
tion of type I IFN signaling 
Low cell type 
specificity 
1Gene annotations supplied by the human protein atlas [55,56] 
2Macaque equivalent of human HLA Class II 
  508 
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Table 2 - Differentially regulated genes in BAL cells obtained from SARS-CoV-2 challenged vac-509 
cinated versus control macaques 510 
 511 
Down-regulated transcripts on Days 5 and 7 Post-Challenge1 
Gene ID Function Distribution Gene ID Function Distribution 




nals required for T cell activa-
tion. Receptor for CD80 
T cell 
CCR1 
C-C chemokine receptor, re-
cruitment of immune effector 
cells 
Macrophages IL1RAP 
Coreceptor with IL1R1 in the  
IL-1 signaling system Neutrophil 
CD274 
Ligand of PD-1 (PDL1), inhib-
its  expansion of antigen-spe-




IL1R2 Decoy receptor for IL1α, IL1β 
(IL1B) inhibiting signaling 
Macrophage, 
neutrophils 
Down-regulated Transcripts on Day 5 or 7 Post-Challenge Down-regulated Transcripts on Day 10 Post-Challenge 
CD80 
Receptor for CD28 and CTLA-
4 on T cells 









β chain of the gamma inter-
feron receptor 









C-X-C chemokine for recruit-





LY96 Confers responsiveness to LPS Macrophages 
IL21 
Regulates proliferation of ma-
ture B and T cells in response 
to activating stimuli 
Activated 
CD4+ T cells, 
NKT cells 
CTSC Cathepsin protease Macrophages 
DPP4 
Protease upregulated in SARS-
CoV-2 [57] Possible viral entry 
receptor [58] 
T cell CD2 TyroBP Mediates NK cell activation 
Macrophages, 
monocytes 
1Gene annotations supplied by the human protein atlas [55,56] 
2Macaque equivalent of human HLA Class II 
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A major difference between pre-challenge BAL samples was that vaccinated macaques had received 513 
prior intratracheal instillation of vaccine formulation containing CpG and MPLA adjuvants. To as-514 
sess the possible effects and efficacy of our vaccination procedure and formulation, we compared 515 
the expression of 60 genes previously reported to be up-regulated, not by antigenic stimulation, but 516 
by adjuvants alone [59-63]. We found 30 out of 60 genes examined to be significantly (p<0.05) and 517 
differentially (> 2 fold) regulated in BAL cells obtained from vaccinated but unchallenged macaques 518 
(Day -7) relative to samples from unchallenged control animals (Day-1) (Supplemental data, Figure 519 
S13). This pattern suggests that BAL-associated cells from vaccinated animals were stimulated by 520 
the adjuvants in the vaccine formulation. As a further measure of vaccination efficiency, we meas-521 
ured BAL immunoreactivity to the peptides via ELISPOT prior to SARS-CoV-2 challenge (Supple-522 
mental data, Figure S14). We observed modest immunoreactivity to one of the six CTL peptides 523 
(LL9) in 3 out of the 4 vaccinated pre-challenge macaques. We did not detect immunoreactivity to 524 
the peptide antigens using samples of peripheral blood mononuclear cells (data not shown). 525 
 526 
4. Discussion 527 
 528 
In our study, SARS-CoV-2 infection in unvaccinated control macaques progressed similar to previ-529 
ous reports using this model. The post-viral challenge period was clinically characterized by 1) two 530 
waves of infectious viral particle recovery in the nasal tissues, 2) lymphopenia on day 1 post-chal-531 
lenge in all animals, and 3) progressive development of pneumonia-like infiltrations visible on chest 532 
x-rays as “ground-glass like consolidations”, but few changes associate with human SARS COV-2 533 
infection such as loss of appetite, respiratory distress, vomiting and/or diarrhea. We observed that 534 
the kinetics of change in viral loads observed in control rhesus macaques were similar to those pre-535 
viously reported [11]. Additionally, the lung tissue abnormalities revealed by chest radiography 536 
were similar in the kinetics of progression and depth to previous reports [6,15,16,20,45-48]. Together, 537 
these observations suggest that SARS CoV-2 infection in the Rhesus model is clinically mild, a con-538 
clusion confirming some [6,8,11], but not all [64] previous reports. SARS-CoV-2 infection in micro-539 
sphere/adjuvant vaccinated macaques progressed in a pattern different from the unvaccinated con-540 
trols. Specifically, disease was characterized by a trend toward diminished recovery of infectious 541 
viral particles from nasal tissues; enhance recovery of peripheral blood lymphocytes counts, and a 542 
significant absence of pneumonia-like infiltrates in the lung. Together, these observations suggest 543 
that vaccination conferred some degree of protection against SARS CoV-2 induced disease. 544 
 545 
Supporting this clinical conclusion were our studies of the gene expression profiles in serially har-546 
vested BAL cells from SARS CoV-2 challenged macaques and immunoreactivity of the BAL cells. In 547 
samples collected from vaccinated (but pre-viral challenge) macaque BAL cells, we found distinct 548 
changes in gene expression associated with the use of TLR 4 and 9 agonists, including up-regulation 549 
of CSF1 [61], IRF7 [62], and IL10[60] suggesting effective delivery of the adjuvant portion of the vac-550 
cine formulation. When we examined HLA Class I restricted immunoreactivity of the pre-challenge 551 
but vaccinated macaque BAL cells towards the vaccinating peptides, we found modest to low reac-552 
tivity towards one of the peptides (LLLDRLNQL) in three of four NHP subjects vaccinated. 553 
 554 
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Following vaccination and viral challenge, we found evidence of up-regulation of both Mamu MHC 555 
Class I and Class II genes in macaque BAL cells relative to unvaccinated, viral challenged macaques. 556 
Upregulation of HLA Class I and Class II molecules in peripheral blood mononuclear cells has been 557 
reported following the measles /mumps/rubella (MMR) vaccine in MMR naïve individuals [65]. In-558 
creased signatures of M1-type macrophage APC transcripts in the BAL of SARS-CoV-2 infected 559 
rhesus macaques has been previously reported [5]; however our finding of upregulated expression 560 
of MHC Class II genes, a hallmark of professional APCs, appears to be unique to the BAL of our 561 
vaccinated macaques. Likewise, we found increased up-regulation of the IL2 genes in vaccinated 562 
relative to unvaccinated macaques. A similar finding has been reported in humans where higher IL 563 
2 levels distinguish mild/asymptomatic forms of COVID-19 disease from the moderate/severe forms 564 
[66].  Following viral challenge in our study (specifically, Day 5 to 7), we found down-regulation of 565 
IFNα2 genes in BAL cells recovered from vaccinated subjects relative to their unvaccinated controls. 566 
The observation perhaps reflects the decreased viral loads found in vaccinated NHP subjects [5]. 567 
 568 
While antibodies are a critical component of the protective humoral immune response to pathogens, 569 
antibodies that promote disease have been described and categorized as ADE [67] or VAERD, such 570 
as that described in MERS-CoV or RSV patients [68-70]. Since our vaccine only delivered low molec-571 
ular weight nonameric synthetic peptides, unconjugated to any carrier, we did not expect to gener-572 
ate a significant anti-peptide humoral response. Rather, during the development and testing of the 573 
microsphere synthetic peptide COVID 19 vaccine, we were mindful of evoking Th2 biased immune 574 
responses, particularly those that occur in the absence of Th1 responses or appropriate T regulatory 575 
cell responses [71]. The gene expression patterns of BAL cells obtained from the vaccinated ma-576 
caques in our study suggested that we did not provoke an unbalanced Th2 response by vaccination. 577 
 578 
We note several weaknesses in our approach to demonstrate the efficacy of this experimental vac-579 
cine: 1) SARS-CoV-2 infection in Rhesus macaques resulted in only mild disease, which appears to 580 
resolve by day 10-14 post-infection. Having noted this in previous reports on the SARS-CoV-2 /rhe-581 
sus model, we tried to induce more severe forms of infection using higher doses of infectious parti-582 
cles than previous reports. Based on clinical signs, we found little effect of the increased dose of the 583 
virus on Rhesus SARS-CoV-2 disease severity. 2) Because of the limited amount of cells recovered 584 
from the BAL, we were where unable to perform confirmatory quantitative RT-PCR analysis of the 585 
unique gene expression patterns found in vaccinated versus control BAL. Nevertheless, we found 586 
that many of our observations have been previously reported from studies in similar models, 3) Not 587 
all the macaque chest radiographs were performed on the same day in control versus vaccinated 588 
subjects, a reflection of the logistic difficulties in working under BSL ¾ conditions. We are confident, 589 
however, we have captured the chest radiographic abnormalities induced by SAR-CoV-2 infection 590 
of macaques (i.e. conspicuous consolidations and infiltrations prevalent in the caudal lobe of the 591 
right lung), and adequately shown their absence in vaccinated viral challenged macaques, 4) we 592 
only included one cynomolgus macaque in our control group. This was primarily due to macaque 593 
availability at the time the study was conducted. However, this appears to have been both a strength 594 
[64] and weakness of the experimental design, as we found similar lung pathology in the cynomol-595 
gus macaque as well as similar patterns of BAL gene expression as the controls Rhesus subjects [72], 596 
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and 5) we did not study the effects of adjuvant alone on SARS-Cov-2 infection in the Rhesus ma-597 
caques. Previous experience with this microsphere CTL vaccine platform in a murine Ebola virus 598 
model has shown that adjuvant alone was not sufficient to confer protection against lethal virus 599 
challenge. Protection was conferred only when the corresponding synthetic CTL peptide epitopes 600 
were delivered in the microsphere [4]. 601 
 602 
We believe this report is the first demonstration of efficacy in a preclinical NHP model of SARS 603 
CoV-2 infection of a synthetic peptide-based vaccine based on known and persistently immuno-604 
genic HLA Class I bound CTL peptide epitopes of SARS nucleoprotein [28]. The SARS-CoV-2 nucle-605 
oprotein genomic sequences have shown significantly reduced mutations rates compared to spike 606 
protein. As such, it may represent an additional target for vaccination, perhaps in the context of a 607 
booster vaccine used following SARS-CoV-2 spike protein vaccines based on recombinant protein, 608 
mRNA, or adenoviral vectors [73-75]. The ready ability to change the sequence of the synthetic pep-609 
tide HLA Class I restricted CTL epitopes used in the system is an attractive feature, given the ob-610 
served rates of mutation in SARS-CoV-2 as it spreads in the human population in the future. A 611 
second potentially attractive feature of this vaccine approach is that it can be delivered by aerosoli-612 
zation to the respiratory mucosa, a route previously demonstrated to generate efficiently lung-613 
dwelling tissue-resident memory T cells [76,77]. 614 
 615 
5. Conclusions 616 
We demonstrate that Rhesus macaques receiving the microsphere vaccine formulation prior to viral 617 
challenge are protected from pneumonia-like lung abnormalities that characterize SARS CoV-2 in-618 
fection in unvaccinated control macaques. Analysis of gene expression of cells obtained from bron-619 
chiolar lavage shows unique signatures consistent with the hypothesis that vaccination with this 620 
platform induces a protective T cell response in viral challenged macaques.  621 
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Supplemental Materials 922 
 923 




Supplemental Data, Figure S1 legend. Core body temperature alterations in vaccinated macaques 928 
prior to SARS-CoV-2 challenge. For each animal, 35 days of pre-challenge temperature measure-929 
ments are shown. Each tick on the x-axis represents 12 hours or 48 individual logger measure-930 
ments.  931 
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Supplemental Data, Figure S2 Legend. Hematological analysis in control and vaccinated macaques 936 
challenged with SARS-CoV-2. The counts of white blood cells (WBC) (upper left panel), the percent 937 
of lymphocytes in WBC (upper right panel), the percent of monocytes in the WBC (lower left panel), 938 
and the percent of neutrophils in the WBC (lower right panel) were analyzed. An asterisk indicates 939 
a statistically significant difference (p< 0.05) between control and vaccinated macaques by Students 940 
t-test.  941 
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Supplemental Data, Figure S3 Legend. Viral clearance rates in control and vaccinated SARS CoV-946 
2 challenged macaques. From the total viral loads measurements in nasal swab samples from SARS-947 
CoV-2 challenged macaques, the daily viral clearance rates (i.e. TCID 50 /mL day n-1 minus TCID 50 /mL 948 
day n) were calculated and averaged over a nine-day period. Red symbols are vaccinated macaques 949 
subjects, control unvaccinated macaque subjects are shown in green symbols.  950 
 951 
.CC-BY-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted April 26, 2021. ; https://doi.org/10.1101/2021.04.24.441228doi: bioRxiv preprint 
 32 of 43 
 
 




Supplemental Data, Figure S4 legend. Chest radiographs of control rhesus macaque RA3830 fol-956 
lowing SARS-CoV-2 challenge. As shown, this animal demonstrated a progression of pulmonary 957 
infiltrates during the acute period (Days 2-5) of disease post-challenge which resolved by study 958 
termination (Day 21). White arrows indicate areas of mild to moderate pulmonary infiltrates seen 959 
as ground glass consolidations.  960 
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Supplemental Data, Figure S4 Legend. Chest radiographs of control rhesus macaque RA3891 fol-965 
lowing SARS-CoV-2 challenge. As shown, this animal demonstrated a progression of pulmonary 966 
infiltrates during the acute period (Days 3-7) of disease post-challenge which resolved by study 967 
termination (Day 21). White arrows indicate areas of mild to moderate pulmonary infiltrates seen 968 
as ground glass consolidations.   969 
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Supplemental Data, Figure S6 Legend. Chest radiographs of control rhesus macaque RA3892 fol-974 
lowing SARS-CoV-2 challenge. As shown, this animal demonstrated a progression of pulmonary 975 
infiltrates during the acute period (Day 3) of disease post-challenge which resolved by study termi-976 
nation (Day 21). White arrows indicate areas of mild to moderate pulmonary infiltrates seen as 977 
ground glass consolidations.  978 
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Supplemental Data, Figure S7 Legend. Chest radiographs of control cynomolgus macaque C72543 983 
following SARS-CoV-2 challenge. As shown, this animal demonstrated a progression of pulmonary 984 
infiltrates 5-10 days post-challenge which resolved by study termination (Day 21). White arrows 985 
indicate areas of mild to moderate pulmonary infiltrates seen as ground glass consolidations. 986 
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Supplemental Data, Figure S8 Legend. Chest radiographs of vaccinated rhesus macaques RA1693 991 
and RA1716 following SARS-CoV-2 challenge. With the exception of increased reticulation relative 992 
to baseline, few abnormalities were observed in collected radiograph images. Note the absence of 993 
infiltrates or consolidation typically seen in the unvaccinated control population.  994 
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Figure S9 995 
 996 
 997 
Supplemental Data, Figure S9 Legend. Chest radiographs of vaccinated rhesus macaques RA3689 998 
and RA3797 following SARS-CoV-2 challenge. Radiographs are unremarkable, other than show-999 
ing increased reticulation relative to baseline, appearing on days 2 through 4, clearing on later im-1000 
aging. In particular, note lack of focal infiltrates or consolidations.  1001 
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Supplemental Data, Figure S10. Hierarchical clustering of gene expression in BAL samples col-1006 
lected from control and vaccinated macaques on Day 5 (left panel), Day 7 (middle panel), and Day 1007 
10 (right panel). 5- and 7- days post SARS-CoV-2 challenge. Heatmap shows significantly (p<0.05) 1008 
up-regulated (red) transcripts and down-regulated (green) transcripts from a total of 730 genes an-1009 
alyzed using the NanoString Non-Human Primate Immunology V2 Panel.  1010 
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Figure S11 1011 
 1012 
 1013 
Supplemental Data, Figure S11 Legend. Intratracheal vaccination with the adjuvanted micro-1014 
sphere peptide vaccine did not promote the expression of Th2 type interleukin cytokine transcripts 1015 
in collected BAL samples relative to levels measured in control macaques. BAL cell gene expres-1016 
sion (shown as scaled counts on the y-axis) of cytokines associated with Th2 T cell responses were 1017 
plotted by study day (x-axis) for each animal prior to and following the SARS-CoV-2 challenge. 1018 
No statistically significant differences between control and vaccinated macaques were found. 1019 
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Figure S12 1020 
 1021 
 1022 
Supplemental Data, Figure S12. Intratracheal vaccination with the adjuvanted microsphere pep-1023 
tide vaccine did not promote the expression of Th2 type interleukin cytokine transcripts in col-1024 
lected BAL samples relative to levels measured in control macaques. BAL cell gene expression 1025 
(shown as scaled counts on the y-axis) of cytokines associated with Th2 T cell responses were plot-1026 
ted by study day (x-axis) for each animal prior to and following the SARS-CoV-2 challenge. No 1027 
statistically significant differences between control and vaccinated macaques were found. 1028 
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Supplemental Data, Figure S13 Legend. Hierarchical clustering of adjuvant-related transcript ex-1033 
pression in BAL samples collected from control and vaccinated macaques prior to virus challenge 1034 
(indicated as Control Pre and Vax Pre). Gene expression analysis identified differentially regulated 1035 
genes in BAL samples obtained on Day -1 from control animals and Day -7 from vaccinated ma-1036 
caques. Heatmap shows significant (p <0.05) differential expression of a series of genes that had 1037 
previously been identified (see main text) as being regulated by adjuvants alone. Up-regulated (red); 1038 
down-regulated (green). Macaque RA 3830 was not sampled on day - 1.   1039 
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Supplemental Data, Figure S14 Legend. Immunoreactivity of BAL-associated cells from vac-1044 
cinated macaques to immunizing peptides prior to SARS-CoV-2 challenge. Dates shown are assay 1045 
date rather than sampling date. Concanavlin A was used as a positive control. 1046 
  1047 
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Supplemental Materials 1048 
 1049 
Supplemental data –Table S1A and S1B  1050 
 1051 




HLA allele (genotypic frequency % world) Aggregate 


































Epitope   
LSPRWYFYY +1 - - + + + + + + - 60.51 
LLLDRLNQL - + - - - - - - - - 39.08 
KTFPPTEPK - - + + - - - - + + 40.03 
GMSRIGMEV - + - - - - - - - - 39.08 
ASAFFGMSR - - + + - - - - + + 40.03 
QQQGQTVTK - - - + - - - - + -  
Epitope Count 1 2 2 4 1 1 1 1 4 2 91.512 
 1052 
Notes: 1. + Indicates positive in-vitro assays for MHC binding and/or T-cell recognition [36]. 2. Calculated as previously 1053 
described[78]  1054 
 1055 
 1056 
Supplemental Table S1B      
Rhesus Mamu MHC Class I coverage – predicted binding 




 A7*01:03    A1*002:02 B*068:01(WB) 
LLLDRLNQL A1*026:01 B:086:01 
(WB) 
 A1*026:01 B*056:01(WB) B*056:01(WB) B*068:01(WB) 
   A1*004:01(WB)  A1*004:01(WB)  
KTFPPTEPK  B*013:01(SB) B*083:01 B:086:01 
(WB) 
B*066:01  B*066:01  
GMSRIGMEV A1*026:01   A1*026:01    
ASAFFGMSR B*013:01(WB) B*083:01  B*066:01  B*066:01  
QQQGQTVTK B*013:01(SB)       
 1057 
Notes: 1. A typical rhesus MHC haplotype may contain two or three expressed Mamu-A genes, and up to nineteen 1058 
distinct Mamu-B-like loci[79],  2. Mamu MHC in italics are predicted to bind based on HLA homology and in-vitro 1059 
analysis [40].  3. Mamu MHC in regular font are predicted to bind based on NetMHCpan 4.1, with a weak binder (WB) 1060 
at top  2% percentile rank and strong binder (SB) at top 0.5% precentile rank.  1061 
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